Boston Scientific(NYSE) BSX

Boston Scientific Corporation makes medical tools that doctors use to treat heart, gut, and nerve problems. These devices help people avoid major surgery and recover faster from various health conditions. The company builds products that fix blocked arteries, manage chronic pain, and treat kidney stones.

Tools for Better Health

• Cardiovascular: Heart and vascular devices, including drug-coated balloons and heart rhythm tools; accounted for $3.624 billion of net sales in the second quarter of 2026.
• Endoscopy: Instruments used to see inside the body and treat digestive conditions; produced $793 million of net sales in the second quarter of 2026.
• Urology: Equipment for treating kidney stones and prostate cancer; generated $684 million of net sales in the second quarter of 2026.
• Neuromodulation: Implantable systems that use electrical signals to manage pain; contributed $341 million of net sales in the second quarter of 2026.

Expanding the Medical Toolbox

• Announced a $14.5 billion deal in Jan. 2026 to buy Penumbra, a company specializing in removing blood clots.
• Acquired Bolt Medical, SoniVie Ltd., and Cortex, Inc. during the first half of 2025 to add new technologies.
• Bought Nalu Medical, Inc. and invested $1.501 billion in MiRus LLC during the first six months of 2026.
• Completed the purchase of Axonics, Inc. in Nov. 2024 to strengthen its urology business.

Innovation in Every Device

The company focuses on less-invasive medicine to reduce healthcare costs and traumatic surgical impacts. It maintains a global manufacturing and marketing network to distribute specialized catheters, stents, and mapping tools across several medical fields.

The Financial Picture

• Reported net sales reached $5.442 billion in the second quarter of 2026, up 7.5% year over year.
• Net income rose to $907 million in the three-month period ended June 30, 2026, up 13.8% year over year.
• The company held $539 million in unrestricted cash and cash equivalents as of June 30, 2026.
• Research and development spending was $554 million in the second quarter of 2026 to support new product pipelines.

Bottom Line

Boston Scientific has shifted from a heart-focused business into a wide-ranging medical technology provider. Its strategy of acquiring new companies and funding internal research helps it adapt to changes in global healthcare.